

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of July 2016

Commission File Number 001-36866

---

**SUMMIT THERAPEUTICS PLC**

(Translation of registrant's name into English)

---

85b Park Drive  
Milton Park, Abingdon  
Oxfordshire OX14 4RY  
United Kingdom  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

FORM 20-F       FORM 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

YES       NO

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

---

---

---

On July 18, 2016, Summit Therapeutics plc (the “Company”) issued a press release announcing the results of the resolutions proposed at the Company’s Annual General Meeting. The related press release is attached hereto as Exhibit 99.1.

The information in this Report on Form 6-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SUMMIT THERAPEUTICS PLC

By: /s/ Erik Ostrowski  
Erik Ostrowski  
Chief Financial Officer

Date: July 18, 2016

#### EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release dated July 18, 2016



**Summit Therapeutics plc**  
 (“Summit” or “the Company”)

#### RESULT OF ANNUAL GENERAL MEETING

**Oxford, UK, 18 July 2016** – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (“DMD”) and *Clostridium difficile* infection, announces that all binding resolutions proposed to shareholders at the Company’s Annual General Meeting (“AGM”) held earlier today were duly passed. Resolution 4, an advisory vote on the Remuneration Report for the year ended 31 January 2016, was not passed.

**Dr Frank Armstrong, Non-Executive Chairman of Summit commented**, “I am pleased that shareholders have voted in favour of all binding votes proposed at our AGM, although it is disappointing that the advisory vote on this year’s Remuneration Report did not receive sufficient support.

“Summit has a pay-for-performance philosophy on remuneration and evaluates performance against the achievement of corporate objectives for the year. The feedback received from shareholders is valued by the Board as we implement our approved remuneration policy that aligns the interests of all stakeholders and our overall objective of developing potentially life transforming medicines to treat DMD and CDI.”

#### About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease *C. difficile* infection. Further information is available at [www.summitplc.com](http://www.summitplc.com) and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

#### Summit

Glyn Edwards / Richard Pye (UK office)  
 Erik Ostrowski / Michelle Avery (US office)

Tel: +44 (0)1235 443 951  
 +1 617 225 4455

#### Cairn Financial Advisers LLP

(Nominated Adviser)  
 Liam Murray / Tony Rawlinson

Tel: +44 (0)20 77148 7900

#### N+1 Singer

(Broker)  
 Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

#### MacDougall Biomedical Communications

(US media contact)  
 Chris Erdman / Karen Sharma

Tel: +1 781 235 3060  
[cerdman@macbiocom.com](mailto:cerdman@macbiocom.com)  
[ksharma@macbiocom.com](mailto:ksharma@macbiocom.com)

#### Consilium Strategic Communications

(Financial public relations, UK)  
 Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville

Tel: +44 (0)20 3709 5700  
[summit@consilium-comms.com](mailto:summit@consilium-comms.com)

-END-